Completed PHASE2 INTERVENTIONAL 2-arm NCT01078389

Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout

A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects With Early Gout

Sponsor: Takeda

Conditions Joint Damage

Interventions Febuxostat Placebo for Febuxostat

Updated 6 times since 2017 Last updated: Sep 3, 2014 Started: Mar 31, 2010 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Joint Damage and is currently completed. Takeda leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Arlington, United States , Arlington Heights, United States , Austin, United States , Avon, United States , Bellevue, United States , Belzoni, United States , Billings, United States , Boynton Beach, United States , Burbank, United States and 46 more locations